A dvances in cardiovascular medicine have resulted in dramatic improvements in patient outcomes. 1 While clearly beneficial for patients, these trends present challenges to researchers developing novel therapies that must demonstrate incremental clinical benefits over existing therapies. As the rates of serious outcome events such as myocardial infarction, stroke, and death in the control group of clinical trials decrease, a new treatment must provide a greater relative risk reduction compared with standard treatment to achieve the same absolute risk reduction.
Tan et al Composite End Point Trends in Cardiovascular Trials
To date, there has been no systematic analysis examining how the use of composite end points in cardiovascular randomized controlled trials has changed over a long-term period. In the present study, we evaluated trends in the use of composite end points in cardiovascular trials in 3 major general medical journals over the past 30 years. In secondary analyses, we assessed whether trials using composite end points have more frequently included components of lesser clinical importance over time.
Methods

Data Sources and Searches
Using a previously validated search strategy for retrieving randomized controlled trials, 10 we searched MEDLINE using the following terms: cardiac, cardiology, cardiovascular, coronary, heart, and myocardial. The search was restricted to studies published between 1986 and December 2015 in the New England Journal of Medicine, the Journal of the American Medical Association, and The Lancet.
Study Selection
Studies required 3 criteria for inclusion. First, the study was a randomized controlled trial of adult patients (>18 years of age). Second, the primary intent of the trial intervention was for treatment or primary or secondary cardiovascular prevention. Trials designed to evaluate the cardiovascular consequences and safety of noncardiovascular agents, such as nonsteroidal anti-inflammatory drugs or chemotherapeutic agents, were excluded. Third, the primary outcome included at least 1 clinical outcome. Examples of clinical primary outcomes included death, myocardial infarction, stroke, cause-specific or allcause hospitalization, revascularization, arrhythmia, or surgical procedures such as valve replacement or cardiac transplant. Trials with primary nonclinical or surrogate outcomes, such as angiographic restenosis, left ventricular ejection fraction, infarct size based on imaging, biomarker changes, exercise testing, cardiovascular risk factors, and symptom-based scoring systems, were not eligible. Trials were excluded if they involved interim analysis or reanalysis of previously published trials (either long-term follow-up or subgroup analysis).
Data Extraction and Quality Assessment
Two authors (S.H.A., N.S.T.) independently extracted data using a standardized form. Data collected included demographics of the study population, type of cardiovascular disease, study intervention, primary outcome, sample size, length of follow-up, and source of funding. Standardized criteria were used to establish whether abstracts of articles identified in the search met the inclusion criteria. Full-text articles were retrieved for all potentially eligible articles and reviewed for eligibility. Any uncertainty on eligibility for inclusion was resolved by discussion. A total of 23 studies were discussed with a third author to clarify inclusion eligibility.
Data Synthesis and Analysis
Study interventions were divided into 4 groups: pharmacological, procedural (including percutaneous coronary intervention, cardiovascular surgery, or electrophysiology studies and ablations), devices (including permanent pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy, transcatheter aortic valve implantation, intra-aortic balloon pump, Swan-Ganz catheters, and left ventricular assist devices), and other interventions (including lifestyle modification or interventions not meeting other criteria). When authors reported >1 coprimary end point, we used a previously described hierarchy 8 to choose the primary end point: (1) authors' explicit designation of the main primary outcome, (2) the primary end point used to calculate sample size, (3) authors' affirmation of importance in their description of the results, and (4) primary end point that appeared first in the Methods section.
For each primary outcome, we abstracted the number of composite components if applicable, the specific components, and the P value for treatment efficacy. We noted whether there was a statistically significant (P<0.05) therapeutic benefit in reducing all-cause mortality and cardiovascular death, which were recorded separately.
The spectrum of health outcomes studied in the trials was of variable importance to patients. We used a previously described hierarchical categorization of the importance of the component end points from cardiology trials, which was developed based on consensus among 11 physicians independently categorizing 72 outcomes contained within composite end points, based on perceived importance to patients. 8 All primary end point components were categorized into 5 categories: (1) death, (2) critical, (3) major, (4) moderate, and (5) minor (Appendix 1).
Statistical Analysis
Continuous variables are presented as means and SDs (or medians and interquartile ranges). Categorical variables are summarized as frequencies and percentages, and comparisons across groups were made using Pearson χ 2 tests. We stratified the clinical trials a priori into 6 time intervals : 1986 to 1990, 1991 to 1995, 1996 to 2000, 2001 to 2005, 2006 to 2010, and 2011 to 2015. Temporal trends in the use of a composite end point in the trials were examined using the Mantel-Haenszel test. The number of components in the primary end point and use of end points with respect to ranked importance over time were analyzed using the Skillings-Mack test. 11 We performed multivariable logistic regression to examine the independent association between the use of composite end points and time period, adjusting for journal, type of study intervention, and type of cardiovascular disease.
To determine whether less treatment benefit was observed for the more clinically important components of a composite end point, we compared the hazard ratio or relative risk point estimates for each end point to the adjacent available end point. For example, in a study using a composite end point with 3 individual components categorized as death, critical, and minor, we would compare the hazard ratio for death to critical and the hazard ratio for critical to minor. A hazard ratio for the critical end point higher than for the minor end point (eg, hazard ratio critical =0.8 versus hazard ratio minor =0.4) would be consistent with the treatment having a relatively smaller benefit on the critical than the minor end point. Comparisons of hazard ratios were dichotomized (higher or lower), without considering their absolute differences. To account for the clustering of these data within trials, we used a generalized linear mixed model with a random intercept. We also performed ancillary analysis with a generalized estimating
WHAT IS KNOWN
• Cardiovascular mortality has declined since the mid20th century, and consequently it has become more difficult to demonstrate the incremental benefits of novel therapies in clinical trials over time.
WHAT THE STUDY ADDS
• The use of composite primary end points has increased markedly in randomized controlled trials of cardiovascular therapies published in the top 3 general medical journals over the past 30 years.
• Over the same period, the number of components within composite end points has increased.
• There has been a trend to add outcomes of less clinical importance to the composite outcome.
• Use of mortality in composite end points has decreased, whereas use of end points of less importance has increased over time. We assessed interobserver agreement between the 2 data abstractors with the κ statistic, using 30 random studies independently abstracted, on the identification of end points and categorization of composite end point components.
Results
Our search strategy retrieved 2607 studies, of which 604 met the inclusion criteria (Figure 1 ). There was excellent agreement on determination of composite end point between data abstractors (κ=1.0), as well as for number of component(s) in the primary end point (κ=0.88) and assignment of component end points into categories based on importance (κ values=0.62-0.91).
Trial Characteristics and Distribution of End Points
The pertinent characteristics of the included trials are summarized (Table) . Most trials studied treatments for coronary artery disease and pharmacological treatments. The majority of trials used a composite primary end point; death was included in the primary end point in 53.2% of the trials and in 87.1% of those trials that used a composite primary end point. There was a median of 3 components to the composite outcomes (interquartile range, 1-3); 9.9% had ≥5 components, and the largest number of components was 14. The primary outcome was statistically significant in 45.7% of trials.
Use of Composite End Points
Composite end points were used to different extents among the various cardiovascular disease subtypes, with higher frequencies in coronary and vascular trials than heart failure, arrhythmia, or other cardiovascular diseases (Table) . Trials that examined pharmacological or procedural interventions were significantly more likely to use a composite end point than those testing devices (both P≤0.001 for pairwise comparisons).
Use of composite end points increased significantly over the study period (Figure 2 ). In multivariable analysis adjusting for journal, type of intervention, and type of cardiovascular disease, the use of composite end point was independently associated with more recent time periods (P for trend <0.001). When compared within the trials, the hazard ratios or relative risks were higher (ie, lower relative risk reduction) for the more important components than the less important components of the primary composite end point (for 160 versus 145 components, respectively, P=0.04). Both the generalized linear mixed model and the generalized estimating equation model produced virtually the same results. Use of a weighted composite end point to attempt to address inequality of component importance was rare (0.5% of trials that used a composite).
13,14
Temporal Trends in the Components of the Composite End Point
The use of all-cause mortality as part of the primary end point decreased significantly over time from 59.0% to 55.4% (Figure 2) . Similarly, the use of death as the only component of the primary end point declined from 53.1% between 1986 and 1990 to 17.9% between 2011 and 2016 (P for trend <0.001). Conversely, there was a steady increase in the inclusion of moderate end points over time from 6.3% to 54.5% (P for trend <0.001). The number of components in the composite end points increased significantly over time, with a median of 3 components between 2011 and 2015, in contrast to a median of 1 component between 1986 and 1990 ( Figure 3 ; P for trend <0.001).
Trials using a composite end point had a trend toward more statistically significant positive results compared with trials using a single end point (47.8% versus 41.2%; P=0.077). However, there was no association between the number of components in the composite end point and statistically significant trial results (P=0.25). The frequency of the least important component of the primary end point was examined over the various time periods (Figure 4) . Whereas between 1986 and 1990, moderate or minor events were the least important components of the primary end point in only 6.3% and 3.1% of trials, respectively, between 2011 and 2015, these increased to 44.6% and 4.5% (P<0.001).
Discussion
Our study demonstrates an increase in the use of composite end points in major cardiovascular randomized controlled trials over the past 3 decades and in the number of components within the primary end point. Trials using a composite end point had a trend toward having more significant results as compared with trials using a single primary end point. These trials also reported relatively smaller benefits from therapy on components with greater clinical importance, suggesting that the significance of the overall composite end point was disproportionately driven by less important outcomes. The use of all-cause mortality as part of the composite end point has decreased over time, whereas the use of end points of moderate or minor importance to patients has increased. Although patients and clinicians may be interested in all recognized effects of a new therapy, their focus is on those with the greatest impact on morbidity and mortality. The increasing use of composite outcomes with components that are of minor or moderate importance has considerable implications. Patients and clinicians must now make treatment decisions based on greater assumptions of benefit in meaningful clinical outcomes than in the past. Use of a variety of outcomes within a composite has the advantage of providing an assessment of the breadth of a treatment's impact. However, studies are seldom adequately powered to determine whether the impact on individual components of a composite outcome is statistically significant. Our findings demonstrate that the magnitude of benefit on individual components in cardiovascular trials is heterogeneous-therapies can have a greater effect on outcomes of lesser importance than on death and critical events. These magnitudes are commonly not reported in contemporary study abstracts or conclusions. If treatment decisions on the use of therapies are based on the results of the primary composite outcome as presented, a reader might assume that the major and minor outcomes are similarly improved. As the costs of new treatments increase, those who pay for health care are increasingly using cost-effectiveness data to decide which treatments to reimburse and under which circumstances, and to negotiate price reductions. High-quality economic evaluations require accurate information about clinically important outcomes. The temporal trend to include less clinically important information in primary outcomes of prominent cardiovascular trials implies that reimbursement and policy decisions may increasingly be based on data that are less readily interpretable.
It seems unlikely that we will see a reversal of the trend that we have observed. Restricting the primary outcome to death or critical end points would require new studies to become much larger or newer treatments to be relatively more effective. The therapeutic advances in cardiovascular medicine over the past several decades have dramatically reduced the rates of these major events, making it ever more challenging for new therapies to demonstrate incremental benefit. With the escalating costs of developing new treatments, we acknowledge that the current paradigm of composite end points may have emerged from necessity. We also recognize that there is inherent subjectivity in the hierarchy of end points with respect to their relative importance based on the perspective one adopts. For example, the outcome of hospitalization, with its associated morbidity, health system expenditures, and economic consequences to patients, may well be considered of major importance in contemporary practice.
To address the relative importance of end points within a composite, several authors have suggested incorporating a weighting system for individual end points based on clinical significance. [15] [16] [17] [18] [19] [20] A scheme for ranking composite end points has previously been outlined. 21 Weighted end points can be applied without compromising study power when the treatment effect is driven by more clinically important end points. 18 However, in our analysis, this approach was rare, with only 2 trials using a weighted composite, representing 0.5% of trials that used a composite primary end point. 13, 14 One such study was the A-HeFT (African-American Heart Failure Trial), which evaluated isosorbide dinitrate plus hydralazine versus placebo in patients with left ventricular systolic dysfunction and New York Heart Association classes III/IV heart failure symptoms. 13 The primary outcome in A-HeFT was a weighted composite end point of death, hospitalization, and quality of life, and a scoring system was devised to account for the apparent inequality in importance of these components. The infrequent utilization of weighted end points is not surprising because no consensus on how individual endpoints should be relatively weighted has been established for cardiovascular trials. For this to become an accepted and readily applied approach, a standardized weighting system specifically for cardiovascular end points may need to be developed a priori.
Not all types of interventions used composite end points to the same extent, with a greater proportion of included studies on pharmacological and procedural interventions using composites than trials studying device therapies. Furthermore, over 80% of device trials included death as part of the primary end point. This may reflect the relative novelty of device technology, and, therefore, the lack of active controls, leading to larger treatment benefits. Therapies such as cardiac resynchronization therapy, implantable cardioverter-defibrillators, and transcutaneous aortic valve implantation have typically been studied in those at highest risk, and, therefore, with the most to gain from successful intervention. Furthermore, device interventions tend to be substantially more costly, and clearly demonstrating an improvement in important outcomes such as death may be required for these therapies to be broadly funded.
We acknowledge several limitations in our study. We restricted included trials to 3 major general medical journals, and it is not known whether cardiovascular trials published in other journals demonstrate the same temporal trends in the use of primary composite outcomes. Not all randomized controlled trials reported end points in a clear and standardized manner. For example, some authors used the term revascularization, whereas others further subdivided this category into percutaneous coronary intervention and coronary bypass surgery. Two trials may thus have appeared to have a different number of components, despite including an identical breadth of end points in their primary outcome. However, this did not impact our ranking of the importance of clinical outcomes and would not explain the temporal trends we observed. There was imperfect agreement between reviewers ranking composite end points for importance, which we attribute to subjective interpretation of the end points rather than a methodological limitation. Our study focused on efficacy end points and did not include end points examining only harms of treatments, although the latter are also of clinical importance.
In conclusion, there has been a marked shift in randomized controlled trials of cardiovascular therapies over the past 3 decades toward more frequent use of composite end points that comprised more components, many of which are of lesser clinical importance. These less important components often drive the overall improvement in the composite clinical end point. This pattern may help trialists seeking and achieving statistically significant results, but clinicians, patients, and policymakers must be mindful of the potential limitations in interpreting the magnitude of the benefits of novel treatments.
